



**Press Release**

Stockholm September 12, 2018

## **THE ACQUISITION OF PELICAN COMPLETED**

---

The earlier announced acquisition of a majority stake of Spitalul Pelican is now completed as all necessary approvals have been granted. The cash flow impact of the acquisition is projected at EUR 23 million, including purchasing price, debt, transfer of certain assets and investments into operations.

Spitalul Pelican will be consolidated from mid-September 2018. Revenue for 2017 was EUR 15 million with an EBITDA of EUR 3.7 million.

***For further information, please contact:***

Paula Treutiger, Corporate Communication and Investor Relations Director

+46 733 666 599

[paula.treutiger@medicover.com](mailto:paula.treutiger@medicover.com)

This information is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 13.30 CEST on 12 September, 2018.

*Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories and the largest markets are Poland and Germany. In 2017, Medicover had revenues around €580 million and 15,900 employees. For more information, go to [www.medicover.com](http://www.medicover.com)*